Martin Christopher Nathan 4

What Happened
Martin Christopher Nathan, a director of Oruka Therapeutics, was granted a derivative award covering 9,136 shares on June 2, 2026. The filing reports the acquisition price as $0.00 per share (derivative security), and the award is reported as an option that vests monthly. This is a compensation grant (not a purchase or sale) and does not represent an immediate cash outlay or sale of stock.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-03 (timely)
• Transaction type: Award/Grant of a derivative security (code A)
• Amount: 9,136 underlying shares; reported price $0.00 per share (derivative)
• Vesting: "The option vests as to 1/12 of the underlying shares monthly from June 2, 2026." (monthly vesting over 12 months)
• Shares owned after transaction: Not specified in the filing
• Filing timeliness: Appears timely (filed the next day); no late-filing flag noted

Context
This is a compensation-related option grant, meaning Nathan did not buy or sell shares — the award gives a future claim to shares that will vest over the coming year. Such grants are common for executives and directors and reflect compensation, not an immediate market vote; purchases by insiders are generally viewed as stronger signals of conviction. For more details or the option exercise price/terms, check the company’s proxy statements or subsequent filings if not fully specified here.